Floatz logo

Hyaluronidase fihj

Plasma Cell Myeloma

Massachusetts General Hospitalprotein_peptidePhase 4 / ApprovedActive
BBB
77/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
95/ 100

Competitive context

497 Active assets in the Plasma Cell Myeloma cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Jonsson Comprehensive Cancer Center
Phase 4BBB
Busulphan
M.D. Anderson Cancer Center
Phase 4BBB
Inno-206
University of Arkansas
Phase 3BBB
Filanesib
PETHEMA Foundation
Phase 2BBB
CYCLOSPORIN A
Seoul National University Hospital
Phase 3BBB

View all 50 →

Same molecule, other indications

Hyaluronidase fihj is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
57 / 100
View asset →
Transplant IneligibleDormant
CCC
Indicative ·
53 / 100
View asset →
transplant rejectionDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →